Overview of Zolfresh

Property	Description
Active ingredient	Zolpidem tartrate
Form	Film-coated tablets
Pharmacological class	Sedative-hypnotic (Non-benzodiazepine Z-drug)
Common use	Short-term management of sleep-onset insomnia
Origin	Synthetic (Imidazopyridine compound)

What Kind of Medicine is Zolfresh (Zolpidem)?

Zolfresh is a prescription-only medicine containing the active substance Zolpidem tartrate, an agent primarily classified as a sedative-hypnotic. Chemically, the compound is synthetic, structurally related to the imidazopyridine group, placing it within the category known as Non-benzodiazepine Z-drugs. Zolpidem tartrate acts as a gamma-aminobutyric acid (GABAA) receptor positive modulator, defining its core pharmacological action. This action means the medicine works by enhancing the brain's natural calming signals to induce sleep. The substance is available as a single-entity product, focusing its therapeutic effect entirely on the targeted action of Zolpidem.

Physical Form and General Therapeutic Purpose

Zolfresh is formulated for the oral route of administration, typically supplied as film-coated tablets. Its general therapeutic purpose is to act as a sleep aid focused on difficulties with sleep initiation. The synthetic compound acts by promoting a state of calm in the brain: it enhances the inhibitory signaling of the natural neurotransmitter GABA, which is responsible for reducing nerve activity. The primary utility of these agents lies in their ability to rapidly induce sleep. This clinically recognized effect is designed to quickly decrease the time required to achieve sleep onset, serving as a therapeutic tool for the short-term management of sleep-onset insomnia in adults. The rapid dissolution of the tablet form is a key feature of this specific Z-drug formulation.

What side effects are possible with Zolfresh?

Possible Side Effects and Safety Information

The safety profile of Zolfresh (zolpidem tartrate) is documented through official regulatory classifications, detailing potential adverse reactions and special safety considerations. Adverse effects are grouped by frequency and the physiological system they affect.

Frequency-Classified Adverse Reactions

Adverse reactions are classified according to regulatory standards:

Very Common (often ge 10%): Headache and next-day somnolence (drowsiness).
Common (1% to le 10%): Dizziness, fatigue, nausea, vomiting, diarrhea, abdominal pain, back pain, and signs of agitation.
Uncommon (0.1% to le 1%): Anterograde amnesia (memory impairment) which typically occurs hours after ingestion, hallucinations, somnambulism (sleepwalking), restlessness, and aggression.

Serious Adverse Reactions and Safety Constraints

Regulatory documents highlight serious adverse reactions that may occur. These include potentially fatal Angioedema (severe swelling of the face, tongue, or throat) and Complex Sleep Behaviors (CSBs), such as sleep-driving or making phone calls while not fully awake, with no memory of the event. Worsening of depression and increased risk of suicidal thoughts are also documented safety concerns.

Safety is formally constrained for specific populations. The medicine is contraindicated in cases of severe hepatic (liver) impairment. Older adults are noted as being more sensitive to the drug's effects, which increases the risk of falls and related injuries. Additionally, the risk of next-day psychomotor impairment is formally increased if less than seven or eight hours of sleep is achieved, or if the medicine is used concomitantly with alcohol or other CNS depressants.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documents define Zolfresh (Zolpidem tartrate) overdose as a progression of Central Nervous System (CNS) depression. Documented manifestations range from somnolence and impairment of consciousness to more severe outcomes, including coma. The regulatory profile states that severe overdose may lead to respiratory compromise (severe respiratory depression) and cardiovascular compromise, with fatal outcomes having been reported.

Required Emergency Actions

The potential for life-threatening consequences dictates that individuals should get emergency help at once or call a poison control center immediately upon suspected overdose. The risk of severe outcomes is explicitly amplified by the concomitant use of alcohol or other CNS-depressant agents, such as opioids.

Supportive Management

Treatment is primarily symptomatic and supportive. Regulatory information confirms that the GABAA antagonist Flumazenil can reverse zolpidem's effects, though its use may carry risks of neurological symptoms. Other official procedures include performing gastric lavage where appropriate, administering intravenous fluids, and monitoring signs like respiration and blood pressure. Zolpidem is stated to be non-dialyzable.

Therapeutic Uses of Zolfresh

What Zolfresh Treats: Main Uses and Benefits

Zolfresh (zolpidem tartrate) is commonly used in adults for managing symptoms related to a sleep problem called insomnia. It is used in situations involving certain distressing symptoms, specifically sleep-onset insomnia.

The medication is relevant for easing symptoms like difficulty falling asleep and can assist with managing episodic or transient sleep disturbances triggered by situational stress or changes in routine. The core therapeutic benefit helps support the facilitation of falling asleep, which assists with maintaining a sense of stability when symptoms are more noticeable. It offers supportive relief for the symptomatic burden of these issues in the adult population, including the elderly. This supportive benefit is considered relevant across adult demographics where additional symptomatic support is needed to help manage symptoms that create noticeable interference with daily stability.

Quick Fact: Relief for Difficulty Falling Asleep

Zolfresh helps support patients during episodes of disruptive symptom manifestations by easing the difficulty in falling asleep at the beginning of the night.

Eligibility and Restrictions for Use

Zolfresh (zolpidem) is primarily indicated for the short-term treatment of insomnia in adults. It should be used only when insomnia is debilitating or causing severe distress.

Who Can Use Zolfresh?

Zolfresh is generally prescribed for adults (18 years and older) who are experiencing difficulty falling asleep. Dosage adjustments may be necessary for elderly patients and those with certain medical conditions, particularly hepatic (liver) impairment, due to reduced drug clearance.

Who Cannot Use Zolfresh?

Zolfresh is contraindicated or requires extreme caution in several patient groups due to increased risk of adverse effects, including:

Children and Adolescents: Not recommended for individuals under 18 years of age.
Hypersensitivity: Patients with a known allergy or hypersensitivity to zolpidem or any inactive components of the formulation.
Severe Hepatic Impairment: The drug is generally contraindicated in cases of severe liver disease as it can worsen encephalopathy.
Sleep Apnea: Individuals with known or suspected severe sleep apnea, unless managed appropriately.
Myasthenia Gravis: Due to the risk of muscle relaxation.

Patients should inform their healthcare provider about their full medical history, including any history of depression, substance abuse, or respiratory problems, as these may impact the safe use of Zolfresh.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define specific interaction patterns for Zolfresh (zolpidem tartrate), primarily involving effects on the central nervous system (CNS) and its metabolic pathways.

Pharmacodynamic Interactions

Co-administration with other CNS depressants (e.g., opioids, antipsychotics, certain antidepressants, and other sedative/hypnotics) results in additive CNS-depressant effects. This formally documented interaction increases the risk of impaired alertness and psychomotor performance. The co-administration of zolpidem and alcohol is strongly not recommended due to a demonstrated additive effect on psychomotor function.

Pharmacokinetic Interactions

Zolpidem is principally metabolized by the enzyme CYP3A4. Interactions with substances that modify this pathway can alter the plasma concentration of zolpidem.

Substance Type	Mechanism	Official Outcome
CYP3A4 Inhibitors (e.g., Ketoconazole)	Reduced metabolism	Increases exposure to zolpidem.
CYP3A4 Inducers (e.g., Rifampin, St. John’s wort)	Increased metabolism	Significantly reduces exposure and effect of zolpidem; co-administration is not recommended.

Timing and Population Notes

For optimal absorption and effect, regulatory labeling advises that Zolfresh must not be taken with or immediately after a meal. Additionally, caution is formally noted for use in patients with mild or moderate hepatic impairment due to reduced drug clearance.

Mechanism of Action

Zolfresh modulates inhibitory neurotransmission in the central nervous system (CNS). It acts selectively on the GABA A receptor complex, the brain's primary inhibitory neurotransmitter receptor. This action influences the activity of neural circuits.

Zolfresh functions as an agonist at the GABA A receptor. It exhibits preferential binding affinity for the alpha1 subunit of the receptor. Binding to this allosteric site increases the frequency of chloride ion channel opening, thereby potentiating GABA's inhibitory effects.

The resultant influx of negatively charged chloride ions causes hyperpolarization of the postsynaptic neuron, making the neuron less excitable. This physiological effect results in the net reduction of neuronal firing rates in targeted areas, modulating inhibitory signals within the brain.

Dosage and Administration Information

How to Use Zolfresh: Official Administration Guidelines

Zolfresh (zolpidem tartrate) is administered strictly by the oral route as a film-coated tablet, following a single-dose nightly regimen. The primary dosing objective is to use the lowest effective dose for the shortest duration necessary, generally not to exceed four weeks, including any period of dose tapering.

Standard adult dosing guidelines establish a gender-specific initial dose. The recommended starting dose for adult women is 5 mg once per night, while for adult men, the starting dose may be 5 mg or 10 mg. Regardless of the starting dose, the maximum permitted dose is 10 mg once daily, and this limit must not be exceeded.

Timing and Special Populations

Adherence to precise timing is essential for proper administration. The medicine must be taken immediately before bedtime when the individual is ready to sleep. A key procedural condition is ensuring that the patient has a full 7 to 8 hours available for sleep after taking the dose, and the dose should not be re-administered during the same night. Ingestion with or immediately after a high-fat meal may slow the absorption and the onset of the medicine's effects.

Specific dosage adjustments are mandated for certain patient populations. For older adults (geriatric patients) and individuals with mild to moderate hepatic impairment, the recommended dose is uniformly 5 mg once daily. Use in patients under 18 years of age is generally not recommended as effectiveness has not been established in this group.

Recent Clinical Evidence

Research evidence / Overview of studies

Research on the Dual-Action Mechanism

Research has explored whether this combination drug may be linked to a decrease in chronic joint pain for participants with severe osteoarthritis.

Studies have investigated the hypothesis that the drug affected the synovial fluid, and whether findings suggested a link with a decrease in pain. Specifically, research examined whether evidence of an improvement in joint mobility was reported within two weeks of initial treatment.

Research on Associated Inflammation

Studies have also evaluated whether this medication was linked to differences in inflammation markers, compared with single-agent treatments. This research examined whether comparisons showed varying results regarding inflammation markers between the combination of the two active components and the single-agent treatments.

Patient Population and Study Focus

Research focused on the initial research context of this drug in a therapy sequence.

The studies included participants with specific levels of kidney impairment, and did not include individuals with severe liver disease. Participants were generally aged between 55 and 75, with a diagnosis of Stage 3 or 4 osteoarthritis. Findings from these specific study populations may not apply to other groups.

Key Studies & References

Non-Inferiority Clinical Trial On The Efficacy And Safety Of Chondroitin Sulfate And Glucosamine Hydrochloride In Combination Versus Celecoxib In Patients With Knee Osteoarthritis (NCT01425853)

How should Zolfresh be stored and disposed of?

Storage and Handling Requirements

Zolfresh (zolpidem tartrate) tablets must be stored at controlled room temperature, maintaining a range of 20° to 25°C (68° to 77°F), as specified in regulatory labeling. The product must be protected from heat, moisture, and direct light, and it is strictly prohibited to freeze the medication. It should be kept in its original, tightly closed container and stored in a secure location, which is a mandatory requirement for this controlled substance (C-IV).

Official Disposal Instructions

Due to the risks associated with this medication, Zolfresh must be disposed of according to specific government guidelines. The preferred method for discarding unused or expired tablets is utilizing a formal drug take-back program. If a take-back option is not immediately accessible, the FDA guidance specifically recommends that zolpidem be immediately flushed down the toilet to prevent accidental ingestion. All medication must be stored out of the reach of children and disposed of according to local regulations.

Zolfresh